FULC
Fulcrum Therapeutics Inc

2,318
Mkt Cap
$581.42M
Volume
759,518.00
52W High
$15.74
52W Low
$2.32
PE Ratio
-7.39
FULC Fundamentals
Price
$8.38
Prev Close
$8.73
Open
$8.68
50D MA
$10.77
Beta
1.33
Avg. Volume
777,958.15
EPS (Annual)
-$1.18
P/B
1.67
Rev/Employee
$0.00
$370.68
Loading...
Loading...
News
all
press releases
HC Wainwright Has Optimistic Outlook of FULC Q1 Earnings
Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Stock analysts at HC Wainwright lifted their Q1 2026 earnings per share (EPS) estimates for shares of Fulcrum Therapeutics in a report issued...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Equities Analysts Issue Forecasts for FULC FY2030 Earnings
Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Equities research analysts at HC Wainwright issued their FY2030 earnings estimates for Fulcrum Therapeutics in a note issued to investors on...
MarketBeat·3d ago
News Placeholder
Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap Down - What's Next?
Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap Down - What's Next...
MarketBeat·3d ago
News Placeholder
Fulcrum Therapeutics Q4 Earnings Call Highlights
Fulcrum Therapeutics (NASDAQ:FULC) shared full 12-week results from the 20-mg cohort of its phase 1b PIONEER trial evaluating pociredir in patients with sickle cell disease, expanding on partial data...
MarketBeat·3d ago
News Placeholder
Fulcrum Therapeutics (NASDAQ:FULC) Releases Quarterly Earnings Results, Meets Expectations
Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.31) earnings per share (EPS) for the quarter, meeting the consensus...
MarketBeat·3d ago
News Placeholder
Fulcrum Therapeutics (NASDAQ:FULC) Trading 6.5% Higher - What's Next?
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Up 6.5% - Should You Buy...
MarketBeat·8d ago
News Placeholder
Fulcrum Therapeutics (FULC) to Release Quarterly Earnings on Tuesday
Fulcrum Therapeutics (NASDAQ:FULC) will be releasing its Q4 2025 earnings before the market opens on Tuesday, February 24. (View Earnings Report at...
MarketBeat·11d ago
News Placeholder
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has received a consensus rating of "Moderate Buy" from the ten analysts that are covering the stock, MarketBeat.com reports. Two research...
MarketBeat·15d ago
News Placeholder
Wall Street Analysts See a 75.71% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High?
The consensus price target hints at a 75.7% upside potential for Fulcrum Therapeutics (FULC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·15d ago
News Placeholder
Fulcrum Therapeutics (NASDAQ:FULC) Trading Up 1.1% - What's Next?
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Up 1.1% - Should You Buy...
MarketBeat·17d ago
<
1
2
...
>

Latest FULC News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.